JP2019523761A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523761A5
JP2019523761A5 JP2018562186A JP2018562186A JP2019523761A5 JP 2019523761 A5 JP2019523761 A5 JP 2019523761A5 JP 2018562186 A JP2018562186 A JP 2018562186A JP 2018562186 A JP2018562186 A JP 2018562186A JP 2019523761 A5 JP2019523761 A5 JP 2019523761A5
Authority
JP
Japan
Prior art keywords
pab
adc
ala
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018562186A
Other languages
English (en)
Japanese (ja)
Other versions
JP7103953B2 (ja
JP2019523761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/035206 external-priority patent/WO2017210288A1/en
Publication of JP2019523761A publication Critical patent/JP2019523761A/ja
Publication of JP2019523761A5 publication Critical patent/JP2019523761A5/ja
Priority to JP2021143103A priority Critical patent/JP7403507B2/ja
Application granted granted Critical
Publication of JP7103953B2 publication Critical patent/JP7103953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018562186A 2016-05-31 2017-05-31 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート Active JP7103953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021143103A JP7403507B2 (ja) 2016-05-31 2021-09-02 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343825P 2016-05-31 2016-05-31
US62/343,825 2016-05-31
PCT/US2017/035206 WO2017210288A1 (en) 2016-05-31 2017-05-31 Antibody drug conjugates having derivatives of amatoxin as the drug

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021143103A Division JP7403507B2 (ja) 2016-05-31 2021-09-02 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2019523761A JP2019523761A (ja) 2019-08-29
JP2019523761A5 true JP2019523761A5 (enExample) 2020-07-09
JP7103953B2 JP7103953B2 (ja) 2022-07-20

Family

ID=60421192

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018562186A Active JP7103953B2 (ja) 2016-05-31 2017-05-31 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート
JP2021143103A Active JP7403507B2 (ja) 2016-05-31 2021-09-02 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021143103A Active JP7403507B2 (ja) 2016-05-31 2021-09-02 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート

Country Status (6)

Country Link
US (2) US11013816B2 (enExample)
EP (1) EP3471771A4 (enExample)
JP (2) JP7103953B2 (enExample)
CN (2) CN109195631B (enExample)
CA (1) CA3025931A1 (enExample)
WO (1) WO2017210288A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025931A1 (en) * 2016-05-31 2017-12-07 Sorrento Therapeutics, Inc. Antibody drug conjugates having derivatives of amatoxin as the drug
AU2017204139B2 (en) 2016-06-17 2018-08-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for the depletion of cells
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
WO2019197654A1 (en) * 2018-04-13 2019-10-17 Heidelberg Pharma Research Gmbh Targeted amatoxin conjugate for the treatment of solid tumors
US20230057350A1 (en) * 2019-01-31 2023-02-23 Hangzhou Dac Biotech Co., Ltd. A conjugate of an amanita toxin with branched linkers
SG11202110287QA (en) * 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
MX2021015887A (es) * 2019-06-24 2022-03-22 Hangzhou Dac Biotech Co Ltd Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
EP4130045A4 (en) * 2020-03-25 2023-12-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. METHOD FOR PREPARING AN ANTIBODY-DRUG CONJUGATE
CN117440832A (zh) 2021-03-03 2024-01-23 索伦托药业有限公司 包括抗bcma抗体的抗体-药物缀合物
WO2022194988A2 (en) 2021-03-19 2022-09-22 Heidelberg Pharma Research Gmbh B-lymphocyte specific amatoxin antibody conjugates
CN113980909B (zh) * 2021-11-16 2022-06-14 江南大学 一种α-鹅膏蕈碱人工抗原、单克隆抗体、杂交瘤细胞株及应用
US20250205350A1 (en) 2022-03-10 2025-06-26 Vivasor, Inc. Antibody-Drug Conjugates and Uses Thereof
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687997A2 (en) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024243706A1 (en) * 2023-06-02 2024-12-05 The University Of British Columbia Amatoxin analogs and uses thereof
CN117683079B (zh) * 2023-12-12 2025-04-04 九洲药业(杭州)有限公司 一种抗体偶联药物连接子的固相合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112919A2 (en) * 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
CA3026727C (en) 2009-04-08 2022-03-22 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
FR2947320B1 (fr) * 2009-06-30 2011-07-22 Valeo Systemes Thermiques Vanne de commande pour un circuit de refroidissement d'un moteur de vehicule automobile
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
HK1208216A1 (en) * 2012-05-15 2016-02-26 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
JP6506262B2 (ja) * 2013-05-31 2019-04-24 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
AU2014337317A1 (en) * 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
US9239324B2 (en) * 2013-12-06 2016-01-19 Gang Chen Antibody-binding protein-drug conjugate and methods of use
JP6895254B2 (ja) * 2013-12-16 2021-06-30 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
US20170151339A1 (en) 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
WO2016001485A1 (en) * 2014-06-30 2016-01-07 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
CA3025931A1 (en) * 2016-05-31 2017-12-07 Sorrento Therapeutics, Inc. Antibody drug conjugates having derivatives of amatoxin as the drug

Similar Documents

Publication Publication Date Title
JP2019523761A5 (enExample)
US10792328B2 (en) Nanocomplexes for delivery of saporin
JP2020063241A5 (enExample)
JP2019512478A5 (enExample)
RU2654210C2 (ru) Нацеливающие аминокислотные липиды
JP2021073272A5 (enExample)
JP2021100937A5 (enExample)
JP2008508315A5 (enExample)
JP2010526091A5 (enExample)
WO2008134761A2 (en) Modification of biological targeting groups for the treatment of cancer
JP2016153410A5 (enExample)
PL184342B1 (pl) Nowe podstawione pochodne purynylowe o aktywności immunomodulującej oraz kompozycja farmaceutyczna je zawierająca
JP2018526321A5 (enExample)
JP2017512752A5 (enExample)
JP2010521485A5 (enExample)
CA2408008A1 (en) Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
CN112424178B (zh) 治疗性树状聚体
US20190284346A1 (en) Novel cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same
JP2020508985A5 (enExample)
JP2002543202A5 (enExample)
ES2774662T3 (es) Derivados de Pt (IV) y nanotransportadores que los comprenden
CN103655517A (zh) 一种Pep-1肽修饰的脑胶质瘤靶向纳米递药系统及其制备方法
US20090069220A1 (en) Dna-binding polyamide drug conjugates
TW201004647A (en) Novel dual targeting antitumoural conjugates
CN102781478A (zh) 用于细胞内靶向增殖和蛋白质合成的聚阴离子多价大分子